[SCHEDULE 13G/A] Ventyx Biosciences, Inc. SEC Filing
Point72 (Point72 Asset Management, Point72 Capital Advisors and Steven A. Cohen) reports beneficial ownership of 5,895,069 shares of Ventyx Biosciences common stock, representing 8.3% of the class as of the close of business on June 30, 2025. The filing clarifies that Point72 Asset Management has shared voting and dispositive power over these Shares held by Point72 Associates, that Point72 Capital Advisors is the general partner, and that Mr. Cohen controls both entities. The statement notes the shares were not acquired to change control of the issuer and that Cubist Systematic Strategies, LLC acts as a sub-advisor for a portion of the reported position.
Point72 (Point72 Asset Management, Point72 Capital Advisors e Steven A. Cohen) dichiara la proprietà effettiva di 5.895.069 azioni ordinarie di Ventyx Biosciences, pari a 8,3% della categoria alla chiusura dell'attività il 30 giugno 2025. Il deposito chiarisce che Point72 Asset Management detiene il potere condiviso di voto e dispositivo su queste azioni detenute da Point72 Associates, che Point72 Capital Advisors è il general partner e che il Sig. Cohen controlla entrambe le entità. La dichiarazione precisa che le azioni non sono state acquisite per modificare il controllo dell'emittente e che Cubist Systematic Strategies, LLC agisce come sub-advisor per una parte della posizione segnalata.
Point72 (Point72 Asset Management, Point72 Capital Advisors y Steven A. Cohen) informa la propiedad beneficiaria de 5.895.069 acciones ordinarias de Ventyx Biosciences, que representan el 8,3% de la clase al cierre de operaciones del 30 de junio de 2025. La presentación aclara que Point72 Asset Management tiene poder compartido de voto y disposición sobre estas acciones mantenidas por Point72 Associates, que Point72 Capital Advisors es el socio general y que el Sr. Cohen controla ambas entidades. El comunicado indica que las acciones no se adquirieron para cambiar el control del emisor y que Cubist Systematic Strategies, LLC actúa como subasesor de una parte de la posición declarada.
Point72(포인트72 자산운용, Point72 Capital Advisors 및 Steven A. Cohen)는 2025년 6월 30일 영업종료 기준으로 Ventyx Biosciences 보통주 5,895,069주, 즉 클래스의 8.3%에 대한 실질적 소유를 보고했습니다. 제출서류는 Point72 Asset Management가 Point72 Associates가 보유한 이 주식들에 대해 공동 의결권 및 처분권을 가지고 있으며, Point72 Capital Advisors가 일반 파트너이고 Cohen 씨가 두 법체를 통제한다고 명시합니다. 성명은 해당 주식이 발행회사에 대한 지배권 변경을 목적으로 취득된 것이 아니며 Cubist Systematic Strategies, LLC가 보고된 포지션의 일부에 대해 서브어드바이저로 활동한다고 밝혔습니다.
Point72 (Point72 Asset Management, Point72 Capital Advisors et Steven A. Cohen) déclare la propriété bénéficiaire de 5 895 069 actions ordinaires de Ventyx Biosciences, représentant 8,3% de la catégorie à la clôture des échanges le 30 juin 2025. Le dépôt précise que Point72 Asset Management détient le pouvoir conjoint de vote et de disposition sur ces actions détenues par Point72 Associates, que Point72 Capital Advisors est le commandité et que M. Cohen contrôle les deux entités. La déclaration indique que les actions n'ont pas été acquises dans le but de changer le contrôle de l'émetteur et que Cubist Systematic Strategies, LLC agit en tant que sous‑conseiller pour une partie de la position déclarée.
Point72 (Point72 Asset Management, Point72 Capital Advisors und Steven A. Cohen) meldet wirtschaftliches Eigentum an 5.895.069 Stammaktien von Ventyx Biosciences, was 8,3% der Aktieklasse zum Börsenschluss am 30. Juni 2025 entspricht. Die Einreichung stellt klar, dass Point72 Asset Management über gemeinsame Stimm- und Verfügungsrechte für diese von Point72 Associates gehaltenen Aktien verfügt, dass Point72 Capital Advisors der Generalpartner ist und dass Herr Cohen beide Einheiten kontrolliert. In der Erklärung heißt es, die Aktien seien nicht zum Zweck der Übernahme der Kontrolle über den Emittenten erworben worden und dass Cubist Systematic Strategies, LLC als Sub-Advisor für einen Teil der gemeldeten Position fungiert.
- Institutional ownership of 8.3% by a prominent asset manager (Point72) signals investor confidence and potential long-term support.
- Clear reporting of shared voting and dispositive power and identification of advisory relationships provides transparency to the market.
- No sole voting or dispositive power
- Concentration at 8.3% is material and could increase market sensitivity to any future changes in the holder's intent or trading activity>
Insights
TL;DR: Point72 discloses an 8.3% passive stake in Ventyx, sizable enough to attract investor attention but below a controlling position.
Point72's reported 8.3% holding is material for a single institutional holder and could influence market liquidity and investor perception of Ventyx (VTYX). The filing specifies shared voting and dispositive power rather than sole control, indicating a coordinated but not unilateral influence on corporate decisions. The statement also affirms the position is not intended to effect control, consistent with a Schedule 13G filing. For analysts, this represents a notable institutional endorsement without immediate governance upheaval.
TL;DR: An 8.3% stake held with shared voting power creates potential for engagement but not direct control or an imminent proxy campaign.
The disclosure shows Point72 exercises shared voting and dispositive powers through managed funds and identifies the chain of control: Point72 Associates, Point72 Asset Management, Point72 Capital Advisors, and Mr. Cohen. The filing’s certification that the position is not intended to change control reduces immediate takeover concerns, but the concentration is large enough that the issuer's board and governance teams may proactively engage with Point72. Sub-advisory involvement by Cubist Systematic Strategies suggests diversified decision processes within the position.
Point72 (Point72 Asset Management, Point72 Capital Advisors e Steven A. Cohen) dichiara la proprietà effettiva di 5.895.069 azioni ordinarie di Ventyx Biosciences, pari a 8,3% della categoria alla chiusura dell'attività il 30 giugno 2025. Il deposito chiarisce che Point72 Asset Management detiene il potere condiviso di voto e dispositivo su queste azioni detenute da Point72 Associates, che Point72 Capital Advisors è il general partner e che il Sig. Cohen controlla entrambe le entità. La dichiarazione precisa che le azioni non sono state acquisite per modificare il controllo dell'emittente e che Cubist Systematic Strategies, LLC agisce come sub-advisor per una parte della posizione segnalata.
Point72 (Point72 Asset Management, Point72 Capital Advisors y Steven A. Cohen) informa la propiedad beneficiaria de 5.895.069 acciones ordinarias de Ventyx Biosciences, que representan el 8,3% de la clase al cierre de operaciones del 30 de junio de 2025. La presentación aclara que Point72 Asset Management tiene poder compartido de voto y disposición sobre estas acciones mantenidas por Point72 Associates, que Point72 Capital Advisors es el socio general y que el Sr. Cohen controla ambas entidades. El comunicado indica que las acciones no se adquirieron para cambiar el control del emisor y que Cubist Systematic Strategies, LLC actúa como subasesor de una parte de la posición declarada.
Point72(포인트72 자산운용, Point72 Capital Advisors 및 Steven A. Cohen)는 2025년 6월 30일 영업종료 기준으로 Ventyx Biosciences 보통주 5,895,069주, 즉 클래스의 8.3%에 대한 실질적 소유를 보고했습니다. 제출서류는 Point72 Asset Management가 Point72 Associates가 보유한 이 주식들에 대해 공동 의결권 및 처분권을 가지고 있으며, Point72 Capital Advisors가 일반 파트너이고 Cohen 씨가 두 법체를 통제한다고 명시합니다. 성명은 해당 주식이 발행회사에 대한 지배권 변경을 목적으로 취득된 것이 아니며 Cubist Systematic Strategies, LLC가 보고된 포지션의 일부에 대해 서브어드바이저로 활동한다고 밝혔습니다.
Point72 (Point72 Asset Management, Point72 Capital Advisors et Steven A. Cohen) déclare la propriété bénéficiaire de 5 895 069 actions ordinaires de Ventyx Biosciences, représentant 8,3% de la catégorie à la clôture des échanges le 30 juin 2025. Le dépôt précise que Point72 Asset Management détient le pouvoir conjoint de vote et de disposition sur ces actions détenues par Point72 Associates, que Point72 Capital Advisors est le commandité et que M. Cohen contrôle les deux entités. La déclaration indique que les actions n'ont pas été acquises dans le but de changer le contrôle de l'émetteur et que Cubist Systematic Strategies, LLC agit en tant que sous‑conseiller pour une partie de la position déclarée.
Point72 (Point72 Asset Management, Point72 Capital Advisors und Steven A. Cohen) meldet wirtschaftliches Eigentum an 5.895.069 Stammaktien von Ventyx Biosciences, was 8,3% der Aktieklasse zum Börsenschluss am 30. Juni 2025 entspricht. Die Einreichung stellt klar, dass Point72 Asset Management über gemeinsame Stimm- und Verfügungsrechte für diese von Point72 Associates gehaltenen Aktien verfügt, dass Point72 Capital Advisors der Generalpartner ist und dass Herr Cohen beide Einheiten kontrolliert. In der Erklärung heißt es, die Aktien seien nicht zum Zweck der Übernahme der Kontrolle über den Emittenten erworben worden und dass Cubist Systematic Strategies, LLC als Sub-Advisor für einen Teil der gemeldeten Position fungiert.